Bladder cancer drug combo trial halted early – what we know
NCT ID NCT04586244
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This phase 2 study tested several drug combinations (retifanlimab, epacadostat, INCAGN02385, INCAGN02390) given before bladder removal surgery in 30 patients with muscle-invasive bladder cancer who could not take the standard chemo drug cisplatin. The trial was terminated early, so the planned analysis of immune cell changes in the tumor could not be fully completed. The main goal was to see if these drugs could boost the body's immune response against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)
Verona, 37124, Italy
-
Hopital Europeen Georges Pompidou (Hegp)
Paris, 75015, France
-
Hospital Saint Louis
Paris, 75475, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
Milan, 20132, Italy
-
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari
Bari, 70124, Italy
-
L Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola - Malpighi
Bologna, 40138, Italy
-
Ohio State University Medical Center Division of H
Columbus, Ohio, 43210, United States
-
Oregon Health & Science University
Portland, Oregon, 97239-4501, United States
-
Universita Campus Bio Medico Di Roma
Roma, 00128, Italy
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
What this could lead to
If successful, this could point toward effective neoadjuvant treatments for bladder cancer patients who cannot use standard chemotherapy.
What could go wrong
The trial was terminated early with limited data, so results are inconclusive. The combinations may not improve outcomes and could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.